Cidara Therapeutics Inc (CDTX)
12.10
-0.61
(-4.80%)
USD |
NASDAQ |
May 16, 16:00
12.10
0.00 (0.00%)
After-Hours: 20:00
Cidara Therapeutics Enterprise Value: 22.20M for May 15, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 15, 2024 | 22.20M |
| May 14, 2024 | 23.94M |
| May 13, 2024 | 22.16M |
| May 10, 2024 | 19.69M |
| May 09, 2024 | 21.70M |
| May 08, 2024 | 23.75M |
| May 07, 2024 | 25.53M |
| May 06, 2024 | 26.31M |
| May 03, 2024 | 21.29M |
| May 02, 2024 | 22.07M |
| May 01, 2024 | 18.10M |
| April 30, 2024 | 18.87M |
| April 29, 2024 | 20.45M |
| April 26, 2024 | 21.84M |
| April 25, 2024 | 23.53M |
| April 24, 2024 | 20.29M |
| April 23, 2024 | 10.98M |
| April 22, 2024 | 11.11M |
| April 19, 2024 | 26.35M |
| April 18, 2024 | 30.09M |
| April 17, 2024 | 30.11M |
| April 16, 2024 | 30.82M |
| April 15, 2024 | 39.46M |
| April 12, 2024 | 38.12M |
| April 11, 2024 | 42.53M |
| Date | Value |
|---|---|
| April 10, 2024 | 47.60M |
| April 09, 2024 | 43.51M |
| April 08, 2024 | 61.19M |
| April 05, 2024 | 69.34M |
| April 04, 2024 | 62.09M |
| April 03, 2024 | 59.37M |
| April 02, 2024 | 61.19M |
| April 01, 2024 | 51.92M |
| March 28, 2024 | 47.59M |
| March 27, 2024 | 40.53M |
| March 26, 2024 | 31.28M |
| March 25, 2024 | 31.86M |
| March 22, 2024 | 34.66M |
| March 21, 2024 | 37.00M |
| March 20, 2024 | 33.37M |
| March 19, 2024 | 28.94M |
| March 18, 2024 | 27.07M |
| March 15, 2024 | 26.29M |
| March 14, 2024 | 22.31M |
| March 13, 2024 | 24.48M |
| March 12, 2024 | 26.20M |
| March 11, 2024 | 24.12M |
| March 08, 2024 | 26.84M |
| March 07, 2024 | 26.12M |
| March 06, 2024 | 27.59M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-18.98M
Minimum
Dec 20 2022
143.50M
Maximum
Mar 21 2023
44.04M
Average
40.54M
Median
Dec 27 2019
Enterprise Value Benchmarks
| Johnson & Johnson | 374.84B |
| NovaBay Pharmaceuticals Inc | 4.622M |
| Palatin Technologies Inc | 23.92M |
| iBio Inc | 16.42M |
| Theriva Biologics Inc | -8.896M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.611M |
| Revenue (Quarterly) | 17.58M |
| Total Expenses (Quarterly) | 23.66M |
| EPS Diluted (Quarterly) | -1.20 |
| Gross Profit Margin (Quarterly) | 93.54% |
| Profit Margin (Quarterly) | -31.91% |
| Earnings Yield | -42.98% |
| Normalized Earnings Yield | -42.98 |